Burkitt lymphoma with heart involvement: features of diagnosis, treatment and follow-up
https://doi.org/10.17650/1818-8346-2025-20-1-88-94
Abstract
Burkitt lymphoma (BL) is a highly aggressive non‑Hodgkin’s lymphoma that characterizes by affecting multiple organs and systems, which explains the diagnosis of the disease at an advanced stage upon the patient’s first medical visit. Heart involvement as part of bL dissemination is extremely rare (2–5 %), but significantly impacts the clinical course, treatment and follow‑up. Heart involvement in bL can manifest as pericardial effusion, myocardial dysfunction or subsequent development of cardiogenic shock. diagnostics of BL with heart involvement should include electrocardiography, echocardiography, N‑terminal fragment of the brain natriuretic propeptide (NT‑proBNP) blood level, myocardial damage markers (troponin I / T), and, if necessary, can include more high‑precision methods – magnetic resonance / computed tomography with intravenous contrast. Timely diagnosis and programmed treatment with rituximab can achieve long‑term survival for BL patients, including advanced stages with heart involvement.
Supporting agencies: The work was performed without external funding
About the Authors
G. A. Radzhabova
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
125993; Build. 1, 2 / 1 Barrikadnaya St.; Moscow
I. V. Osipova
Children’s Republican Clinical Hospital, Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
420138; 140 Orenburgsky Tract St.; Kazan
T. T. Valiev
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Timur Teymurazovich Valiev
125993; Build. 1, 2 / 1 Barrikadnaya St.; 155522; 24 Kashirskoe Shosse; 119991; Build. 2, 8 Trubetskaya St.; Moscow
L. R. Turkiya
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
155522; 24 Kashirskoe Shosse; Moscow
L. R. Karimova
Children’s Republican Clinical Hospital, Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
420138; 140 Orenburgsky Tract St.; Kazan
S. N. Mikhailova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
155522; 24 Kashirskoe Shosse; Moscow
References
1. Tzani A., Doulamis I.P., Mylonas K.S. et al. Cardiac tumors in pediatric patients : a systematic review. World J Pediatr Congenit Heart Surg 2017;8(5):624–32. DOI: 10.1177/2150135117723904
2. Uzun O., Wilson D.G., Vujanic G.M. et al. Cardiac tumours in children. Orphanet J Rare Dis 2007;2:11. DOI: 10.1186/17501172211
3. Bruce C.J. Cardiac tumours: diagnosis and management. Heart 2011;97(2):151–60. DOI: 10.1136/hrt.2009.186320
4. Dozzo M., Carobolante F., Donisi P.M. et al. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther 2016;8:11–29. DOI: 10.2147/AHMT.S94170
5. Toma P., Granata C., Rossi A., Garaventa A. Multimodality imaging of Hodgkin disease and nonHodgkin lymphomas in children. Radiographics 2007;27(5):1335–54. DOI: 10.1148/rg.275065157
6. Valiev T.T. Modern strategy for the diagnosis and treatment of non-Hodgkin’s lymphomas in children. Abstract dis. … doctor of medical sciences. Moscow, 2014. (In Russ.).
7. Tao T.Y., YahyaviFirouzAbadi N., Singh G.K., Bhalla S. Pediatric cardiac tumors: clinical and imaging features. Radiographics 2014;34(4):1031–46. DOI: 10.1148/rg.344135163
8. Armenian S.H., Hudson M.M., Mulder R.L. et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16(3):e123–36. DOI: 10.1016/S14702045(14)704097
9. Lipshultz S.E., Adams M.J., Colan S.D. et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association [published correction appears in Circulation 2013;128(19):e394]. Circulation 2013;128(17):1927–95. DOI: 10.1161/CIR.0b013e3182a88099
10. GómezPrieto P., López T., Moreno M. et al. Early detection of chemotherapyinduced cardiotoxicity in hematological patients: a prospective study. Blood 2016;128(22):5988. DOI: 10.1182/blood.V128.22.5988.5988
11. Ohtani K., Fujino T., Ide T. et al. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline induced cardiotoxicity. Clin Res Cardiol 2019;108(6):600–11. DOI: 10.1007/s0039201813860
12. Nakayama T., Oshima Y., Kusumoto S. et al. Clinical features of anthracyclineinduced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: a singlecenter, retrospective observational study. EJHaem 2020;1(2):498–506. DOI: 10.1002/jha2.110
13. Plana J., Galderisi M., Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15(10):1063–93. DOI: 10.1093/ehjci/jeu192
14. Armstrong G.T., Joshi V.M., Ness K.K. et al. Comprehensive echocardiographic detection of treatmentrelated cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 2015;65: 2511–22. DOI: 10.1016/j.jacc.2015.04.013
15. Marwick T.H. Cancer therapyrelated cardiac dysfunction: unresolved issues. Can J Cardiol 2016;32(7):842–6. DOI: 10.1016/j.cjca.2016.05.001
16. Tocchetti C.G., Cadeddu C., Di Lisi D. et al. From molecular mechanisms to clinical management of antineoplastic druginduced cardiovascular toxicity : a translational overview. Antioxid Redox Signal 2019;30(18):2110–53. DOI: 10.1089/ars.2016.6930
Review
For citations:
Radzhabova G.A., Osipova I.V., Valiev T.T., Turkiya L.R., Karimova L.R., Mikhailova S.N. Burkitt lymphoma with heart involvement: features of diagnosis, treatment and follow-up. Oncohematology. 2025;20(1):88-94. (In Russ.) https://doi.org/10.17650/1818-8346-2025-20-1-88-94
Views:
212
Email this article 